Middleton Family Medicine Urgent Care, Llc

CLIA Laboratory Citation Details

2
Total Citations
10
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 22D0943417
Address 147 South Main St, Middleton, MA, 01949
City Middleton
State MA
Zip Code01949
Phone978 774-2555
Lab DirectorADRIANO PIRIS

Citation History (2 surveys)

Survey - April 14, 2026

Survey Type: Special

Survey Event ID: TK2311

Deficiency Tags: D2016 D6016 D0000 D2096 D6000

Summary:

Summary Statement of Deficiencies D0000 Based on a desk review of proficiency testing (PT) record for 2025 and 2026, the laboratory failed to meet the following conditions, resulting in an initial unsuccessful PT participation: D2016 - 42 C.F.R. 493.803 Condition: Successful participation [proficiency testing] D6000 - 42 C.F.R. 493.1403 Condition: Laboratories performing moderate complexity testing; laboratory director D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a desk review of proficiency testing (PT) records from the Certification and Survey Provider Enhanced Reporting (CASPER) 0155 report and American Proficiency Institute (API) PT Chemistry - Core 2025 and 2026 testing records, the Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- laboratory failed to successfully participate the specialty of Chemistry for the analyte of AST/SGOT. Refer to D2096 D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a proficiency testing (PT) desk review of CASPER 0155 report and API PT 2025 Chemistry Core Event 3 and 2026 Chemistry Core Event 1 records, the laboratory failed to achieve successful performance for the analyte AST/SGOT in two out of three testing events. Findings include: 1. Review of the CASPER 0155 report revealed the following results: API Chemistry Core 2025-3rd Event the laboratory received an unsatisfactory score of 60% for AST/SGOT. API Chemistry Core 2026- 1st Event the laboratory received an unsatisfactory score of 40% for AST/SGOT. 2. Review of the 2025 and 2026 API Chemistry Core Proficiency Testing records confirmed the laboratory received the above results. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on a proficiency testing desk review of CASPER 0155 report and American Proficiency Institute (API) Proficiency Testing 2025 and 2026 records, the laboratory director failed to provide overall management and direction of the laboratory services. The laboratory director failed to ensure proficiency testing samples were tested as required. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a proficiency testing desk review of CASPER 0155 report and API 2025 and 2026 PT records, the laboratory director failed to ensure PT samples were tested as required. The laboratory director failed to ensure successful participation in an HHS approved proficiency testing program. Refer to D2096. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - August 5, 2021

Survey Type: Special

Survey Event ID: IHBQ11

Deficiency Tags: D2016 D2130 D0000 D2016 D2130

Summary:

Summary Statement of Deficiencies D0000 Based on evidence of unsuccessful proficiency testing performance for the Platelet count analyte, the following Condition level deficiency was deemed to be not met: Condition 42 CFR 493.803 - Proficiency Testing - Successful Participation. . D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on proficiency testing performance review for calendar years 2020 and 2021 (three testing events), the laboratory failed to successfully participate (achieve a score of 80 percent or more) in a proficiency testing program for the platelet count analyte. The laboratory achieved performance scores of forty (40) percent for the third testing event of 2020 and sixty (60) percent for the second testing event of 2021 for the Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- platelet count analyte. Based on this evidence the laboratory failed to undertake the appropriate training and/or technical assistance necessary to correct the problem of unsuccessful proficiency testing performance for the platelet count analyte. D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on proficiency testing performance review for calendar years 2020 and 2021 (three testing events), the laboratory failed to achieve satisfactory performance for the same analyte for two out of three proficiency testing events as evidenced by the following: The laboratory achieved performance scores of forty (40) percent for the third testing event of 2020 and sixty (60) percent for the second testing event of 2021 for the Platelet count analyte resulting in unsuccessful performance for the analyte. Refer to D2016. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access